{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:04:22Z","timestamp":1784354662946,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Premedication with corticosteroids is recommended for prophylaxis against infusion-related reactions (IRRs) caused by obinutuzumab despite a lack of solid evidence regarding the dose of corticosteroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The incidence rates of IRR in the high-dose and low-dose corticosteroid groups were investigated and compared using Student\u2019s t-test.Univariable and multivariable logistic regression analyses were performed on patients to explore the risk of developing IRRs with obinutuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The incidence of IRRs in the high-dose and low-dose corticosteroid groups at the initial administration of obinutuzumab was 27.0% (41\/152) and 48.4% (31\/64), respectively, indicating that the high-dose group had a lower incidence of IRRs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). The incidence of IRRs at the initial administration of obinutuzumab was significantly associated with the administration of first-generation histamine 1 receptor antagonist (OR\u2009=\u20093.31, 95% CI: 1.16\u20139.47; reference: second-generation histamine 1 receptor antagonist), hydrocortisone (OR\u2009=\u20097.21, 95% CI: 1.57\u201333.15; reference: dexamethasone), and methylprednisolone (OR\u2009=\u20093.99, 95% CI :1.13\u201314.10; reference: dexamethasone), although no association was found with the lower dose of corticosteroids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although no association was found between corticosteroid dosage and IRR when considering multiple factors, dexamethasone may be a better option than hydrocortisone or methylprednisolone for preventing IRR. Additionally, second-generation H1-receptor antagonists may be a better option than first-generation drugs. Certain combinations of premedications may influence infusion reaction incidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00546-6","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:31:54Z","timestamp":1770121914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study"],"prefix":"10.1186","volume":"12","author":[{"given":"Tatsuya","family":"Ohtsubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Matumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuka","family":"Sasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Tomishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Dote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Makihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Wakasugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Mitsuie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yamagiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kitahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Tomogane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"546_CR1","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331\u201344.","journal-title":"N Engl J Med"},{"key":"546_CR2","unstructured":"National Comprehensive Cancer Network Inc. NCCN clinical practices in oncology; B-cell lymphomas-verssion2 [Internet]. 2024 [cited 2024 April 30]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"546_CR3","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","volume":"36","author":"BD Cheson","year":"2018","unstructured":"Cheson BD, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus Bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36:2259\u201366.","journal-title":"J Clin Oncol"},{"key":"546_CR4","unstructured":"Food & Drug Administration. Drugs @FDA: FDA-Approved Drugs. obinutuzumab drug label. November, 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125486s034lbl.pdf. Date accessed: July 17, 2024."},{"key":"546_CR5","unstructured":"European Medical Agency. Drugs @EMA: EMA-Approved Drugs. obinutuzumab drug label. July, 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gazyvaro-epar-product-information_en.pdf. Date accessed: July 17, 2024."},{"key":"546_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"546_CR7","doi-asserted-by":"crossref","unstructured":"Hayama T, Miura K, Uchiike A, Nakagawa M, Tsutsumi D, Sakagami M, et al. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. Int J Clin Pharm. 2017;39:380-5.","DOI":"10.1007\/s11096-017-0429-3"},{"key":"546_CR8","doi-asserted-by":"crossref","unstructured":"Tachi T, Yasuda M, Usui K, Umeda M, Nagaya K, Osawa T, et al. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin\u2019s lymphoma. Pharmazie. 2015;70:674\u20137.","DOI":"10.31083\/ph.2015.5620"},{"key":"546_CR9","first-page":"1145","volume":"21","author":"J Hong","year":"2013","unstructured":"Hong J, Kim JY, Ahn HK, Lee SM, Sym SJ, Park J, et al. Bone marrow involvement is predictive of infusion related reaction during rituximab administration in patients with B cell lymphoma. Support Care Cancer. 2013;21:1145\u201352.","journal-title":"Support Care Cancer"},{"key":"546_CR10","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/bcp.15675","volume":"89","author":"E Goto","year":"2023","unstructured":"Goto E, Hata T, Nishihara M, Neo M, Iwamoto M, Kimura K, et al. Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab. Br J Clin Pharmacol. 2023;89:2102\u201312.","journal-title":"Br J Clin Pharmacol"},{"key":"546_CR11","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/blood-2015-09-670802","volume":"126","author":"CL Freeman","year":"2015","unstructured":"Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126:2646\u20139.","journal-title":"Blood"},{"key":"546_CR12","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s00277-022-04987-5","volume":"101","author":"Y Masamoto","year":"2022","unstructured":"Masamoto Y, Taoka K, Maki H, Kurokawa M. Bone marrow involvement is a risk factor for infusion-realated reactions in patients with follicular lymphoma treated by obinutuzumab,Annals of hematology. Ann Hematol. 2022;101:2795\u20137.","journal-title":"Ann Hematol"},{"key":"546_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1067\/mcp.2000.110772","volume":"68","author":"T Varis","year":"2000","unstructured":"Varis T, Kivist\u00f6 KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor Itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther. 2000;68:487\u201394.","journal-title":"Clin Pharmacol Ther"},{"key":"546_CR14","unstructured":"Post TW, editor. Glucocorticoid therapy: Pharmacology and principles of use. In: UpToDate, Waltham. MA: UpToDate Inc.; Available at: https:\/\/www.uptodate.com. Accessed [January 8, 2026]."},{"key":"546_CR15","unstructured":"Anaphylaxis MA. UpToDate Inc. Available at: https:\/\/www.uptodate.com. Accessed [January 8, 2026]."},{"key":"546_CR16","doi-asserted-by":"publisher","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","volume":"11","author":"GE Fouda","year":"2020","unstructured":"Fouda GE, Bavbek S. Rituximab hypersensitivity; from clinical presentation to management. Front Pharmacol. 2020;11:572863.","journal-title":"Front Pharmacol"},{"key":"546_CR17","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","volume":"124","author":"PJ Brennan","year":"2009","unstructured":"Brennan PJ, Rodriguez Bouza TR, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124:1259\u201366.","journal-title":"J Allergy Clin Immunol"},{"key":"546_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","volume":"3","author":"VR Galv\u00e3o","year":"2015","unstructured":"Galv\u00e3o VR, Castells MC. Hypersensitivity to biological agents\u2014Updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015;3:175\u201385.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"546_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1345\/aph.18276","volume":"33","author":"GL Kamm","year":"1999","unstructured":"Kamm GL, Hagmeyer KO. Allergic-type reactions to corticosteroids. Ann Pharmacother. 1999;33:451\u201360.","journal-title":"Ann Pharmacother"},{"key":"546_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.5649\/jjphcs.45.396","volume":"45","author":"N Matsui","year":"2019","unstructured":"Matsui N, Ishihara N, Mochizuki Y, Tamaki H, Nishimura N, Naora K. Inhibitory effect on rituximab-induced infusion reaction by premedication with Fexofenadine or bepotastine. Jpn J Pharm Health Care Sci. 2019;45:396\u2013403.","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"546_CR21","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1177\/1078155218811505","volume":"25","author":"CG Durham","year":"2019","unstructured":"Durham CG, Thotakura D, Sager L, Foster J, Herrington JD. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions. J Oncol Pharm Pract. 2019;25:1396\u2013401.","journal-title":"J Oncol Pharm Pract"},{"key":"546_CR22","doi-asserted-by":"publisher","first-page":"e54882","DOI":"10.2196\/54882","volume":"13","author":"Y Kitahiro","year":"2024","unstructured":"Kitahiro Y, Yamamoto K, Yakushijin K, Ioroi T, Tanda M, Itohara K, et al. The efficacy of bepotastine besilate compared with hydroxyzine pamoate for preventing infusion reactions to the first dose of rituximab in patients with Non-Hodgkin lymphoma: protocol for a phase II, Double-Blind, multicenter randomized trial. JMIR Res Protoc. 2024;13:e54882.","journal-title":"JMIR Res Protoc"},{"key":"546_CR23","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Ha\u00efoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the groupe d\u2019etude des lymphomes Folliculaires. groupe d\u2019etude des lymphomes de l\u2019adulte. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"key":"546_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.5649\/jjphcs.47.631","volume":"47","author":"M Kuromatsu","year":"2021","unstructured":"Kuromatsu M, Kajita T, Taruno M, Nishikawa Y, Akasaka T, Okuno T. Search for risk factors influencing the occurrence of infusion reaction after initial treatment with obinutuzumab. Jpn J Pharm Health Care Sci. 2021;47:631\u20138.","journal-title":"Jpn J Pharm Health Care Sci"}],"updated-by":[{"DOI":"10.1186\/s40780-026-00605-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000}}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00546-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00546-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00546-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:33:07Z","timestamp":1784352787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00546-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00546-6","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the author name.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40780-026-00605-y","URL":"https:\/\/doi.org\/10.1186\/s40780-026-00605-y","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study conformed to the provisions of the Declaration of Helsinki. The Institutional Review Board of Japanese Red Cross Kyoto Daini Hospital approved the study protocol (Approval No. S2021-25).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27"}}